MedTwenty

Leeds Teaching Hospitals awards £337,500 Oncotype DX test contract to Exact Sciences UK

A Contracts Finder notice records a two-year award for the Oncotype DX breast recurrence score test, called off from a framework agreement. The notice gives a value range of £337,500 to £405,000.

MedTwenty Editorial··4 min read

Share
A copper-coloured awareness ribbon, a stained tissue sample on a glass slide, a microscope, and laboratory test tubes arranged on a clinical laboratory workbench.
A copper-coloured awareness ribbon, a stained tissue sample on a glass slide, a microscope, and laboratory test tubes arranged on a clinical laboratory workbench.

Leeds Teaching Hospitals NHS Trust has awarded a contract for the Oncotype DX breast recurrence score test to Exact Sciences UK, Ltd., according to a notice published on Contracts Finder on 26 October 2026.

The award value is £337,500. The notice gives an overall value range of £337,500 to £405,000. The data provided does not explain what the upper figure represents, and it does not say whether the values include VAT.

Contract details

The contract runs from 1 July 2026 to 30 June 2028, a two-year term. The notice records the award date as 26 October 2026, which is later than the stated contract start date. The tender deadline was 30 June 2026, and the notice status is closed.

The trust classed the contract as products, with a pathology services CPV code (85111800). The region is listed as "any region". The notice records the procedure as a call-off from a framework agreement, but the data provided does not name the framework. Exact Sciences UK is recorded as an SME.

Why this supplier

The notice describes Oncotype DX as a clinically validated multigene assay for predicting the likely benefit of chemotherapy in "this patient population". It adds that the test is "uniquely available from the current supplier on the global market". The text provided does not define the patient population.

The published title of the notice reads "Ono type DX Breast Recurrence Score Test", while the description refers to Oncotype DX. This appears to be a spelling difference within the notice itself.

The notice does not state how many tests the trust expects to buy, the price per test, or whether the contract includes extension options. It also does not say whether the trust expects the £405,000 upper figure to be reached.

Why it matters

The notice shows an NHS trust buying a genomic breast cancer test through a framework call-off, with the trust stating that the assay is uniquely available from its current supplier. This could signal stable, contract-based demand for the test in NHS pathology and oncology services. Other buyers and competing diagnostics suppliers may want to read the full notice for the framework and value details, which the data provided does not give.

Source: Contracts Finder